๐Ÿ”ฌDeep Research

DMRA โ€” Damora Therapeutics Inc ยท catalysts, narrative & risks

ยท22 sourcesDMRA forecast โ†’

Damora Therapeutics, Inc. (NASDAQ: DMRA) โ€” Research Summary (as of October 25, 2026)

Below is a synthesis of primary-company disclosures, analyst commentary, and market data. This is not investment advice.

Current Snapshot

  • Last close $21.09 on October 23, 2026; market cap ~$1.30B; Beta 1.43; EPS (TTM) -0.25; net income (TTM) -241.25M; total cash ~$540.52M [16].
  • 52-week range: $16.50 (March 20, 2026) to $34.89 (July 20, 2026) [9], [20].
  • Company: a Massachusetts-based biotech developing subcutaneous biologics for mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (ET and MF), with lead asset DMR-001 [5], [22].

AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’